Greenland Mines Ltd (GRML) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Greenland Mines Ltd (formerly Klotho Neurosciences, Inc.) underwent a strategic transformation in March 2026, acquiring Greenland Mines Corp. and renaming itself to reflect a dual-segment business model: Mining (focused on the Skaergaard Project in Greenland) and Biotech (focused on ALS and neurodegenerative disease treatments). The company is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(13,857,203) | $(2,116,726) |
| Net Loss Per Share (Basic/Diluted) | $(0.15) | $(0.08) |
| Cash and Cash Equivalents (End of Period) | $10,002,477 | $565,869 |
| Net Cash Used in Operating Activities | $(4,971,143) | $(1,553,747) |
| Net Cash Provided by Financing Activities | $8,162,329 | $2,055,875 |
| Total Assets | $59,737,093 | $9,593,240 |
| Total Liabilities | $8,268,533 | $129,764 |
| Stockholders' Equity | $51,468,560 | $9,463,476 |
Material Changes vs. Prior Period
- Asset Acquisition: The company acquired mineral rights and exploration licenses for the Skaergaard Project for a total consideration of approximately $48.4 million, primarily paid via the issuance of Series C Preferred Stock ($47.94 million) and cash ($365,324). This drove total assets from ~$9.6M to ~$59.7M.
- Operating Expenses: Total operating expenses surged to $9.5 million from $1.6 million, driven by increased professional fees ($3.0M vs $0.7M) and general/administrative costs ($6.2M vs $0.9M) related to the merger and public company compliance.
- Non-Cash Charges: Significant non-cash expenses impacted the net loss, including a $2.3 million increase in the fair value of warrant liabilities and a $2.0 million impairment charge on biotech intangible assets (generic drug licenses).
- Financing: The company raised approximately $7.75 million in gross proceeds from a private placement of common stock and warrants in March 2026.
Outlook, Risks, and Management Commentary
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months without additional funding due to recurring losses and negative operating cash flows.
- NASDAQ Compliance: The company received a delinquency notification for failing to maintain a $1.00 minimum bid price. It was granted an extension until September 14, 2026, to regain compliance or face delisting.
- Subsequent Events: On May 20, 2026, the company entered an agreement to acquire Neo North Star Resources (Sarfartoq Rare Earth Element Project) for $35 million ($20M cash, $15M stock).
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting as of December 31, 2025, citing inadequate accounting resources and lack of segregation of duties. Remediation efforts were initiated by March 31, 2026.
Investor Verification Checklist
- Capital Adequacy: Verify the timeline and certainty of future equity/debt financing required to sustain operations given the "Going Concern" warning.
- Asset Valuation: Review the valuation methodology for the $48.4M mineral rights acquisition and the impairment rationale for the $2.0M biotech asset write-down.
- Warrant Liability: Monitor the volatility of the $7.7M warrant liability, which significantly impacts net loss through fair value adjustments.
- Listing Status: Track the stock price to ensure compliance with the $1.00 minimum bid price requirement by September 2026.
- Subsequent Acquisition: Assess the financial impact and funding sources for the $35M acquisition of Neo North Star Resources announced in May 2026.